Table 3 The detailed information of nine prognostic mRNAs significantly associated with overall survival in patients with endometrial cancer
mRNA | Ensemble ID | Location | Β (Cox) | HR | p |
|---|---|---|---|---|---|
CLDN9 | ENSG00000213937 | chr 16: 3,012,923–3,014,505 | 0.1059 | 1.1117 | 0.0258 |
B4GALT1 | ENSG00000086062 | chr 9: 33,104,082–33,167,356 | − 0.2504 | 0.7785 | 0.0203 |
GMPPB | ENSG00000173540 | chr 3: 49,716,844–49,723,951 | − 0.4346 | 0.6475 | 0.0134 |
B4GALT4 | ENSG00000121578 | chr 3: 119,211,732–119,240,946 | − 0.3041 | 0.7378 | 0.0839 |
AK4 | ENSG00000162433 | chr 1: 65,147,549–65,232,145 | 0.3181 | 1.3746 | 0.0015 |
CHST6 | ENSG00000183196 | chr 16: 75,472,052–75,495,445 | − 0.1191 | 0.8878 | 0.0665 |
PC | ENSG00000173599 | chr 11: 66,848,417–66,958,439 | 0.328 | 1.3882 | 0.0233 |
GPC1 | ENSG00000063660 | chr 2: 240,435,663–240,468,076 | 0.2056 | 1.2282 | 0.1022 |
SRD5A3 | ENSG00000128039 | chr 4: 55,346,242–55,373,100 | 0.2345 | 1.2643 | 0.05 |